184 Ces Urol 2022; 26(3): 174–185 PŘEHLEDOVÉ ČLÁNKY 13. Hildebrandt B, Wust P, Ahlers O, et al. The cellular and molecular basis of hyperthermia Crit Rev Oncol Hematol 2002; 43(1): 33–56 14. Haveman J, Smals OA, Rodermond HM. Effects of hyperthermia on the rat bladder: a pre‑clinical study on thermometry and functional damage after treatment Int J Hyperthermia 2003; 19: 45–57 15. Oei AL, Kok HP, Oei SB, et al. Molecular and biological rationale of hyperthermia as radio- and che‑ mosensitizer Adv Drug Deliv Rev 2020; 163–164: 84–97 16. Issels RD. Hyperthermia adds to chemotherapy European journal of cancer (Oxford, England: 1990) 2008; 44(17): 2546–2554 17. Maeda H, Tsukigawa K, Fang J. A Retrospective 30 Years After Discovery of the Enhanced Permeability and Retention Effect of Solid Tumors: Next‑Generation Chemotherapeutics and Photodynamic Therapy‑ -Problems, Solutions, and Prospects Microcirculation (New York, NY: 1994) 2016; 23(3): 173–182 18. Au JL, Wientjes MG. Combination intravesical hyperthermia and chemotherapy for bladder cancer Oncology (Williston Park) 2010; 26: 1155–60 19. Inman BA, Etienne W, Rubin R, et al. The impact of temperature and urinary constituents on urine viscosity and its relevance to bladder hyperthermia treatment Int J Hyperthermia 2013; 29: 206–10 20. van der Heijden AG, Dewhirst MW. Effects of hyperthermia in neutralising mechanisms of drug resi‑ stance in non‑muscle‑invasive bladder cancer Int J Hyperthermia 2016; 32(4): 434–45 21. Franke K, Kettering M, Lange K, Kaiser WA, Hilger I. The exposure of cancer cells to hyperthermia, iron oxide nanoparticles, and mitomycin C influences membrane multidrug resistance protein expression levels Int J Nanomed 2013; 8: 351–63 22. Evans SS, Repasky EA, Fisher DT. Fever and the thermal regulation of immunity: the immune system feels the heat Nature reviews Immunology 2015; 15(6): 335–349 23. Milani V, Noessner E, Ghose S, et al. Heat shock protein 70: role in antigen presentation and immune stimulation Int J Hyperthermia 2002; 18(6): 563–575 24. Arends TJ, Falke J, Lammers RJ, et al. Urinary cytokines in patients treated with intravesical mitomycin ‑C with and without hyperthermia World J Urol 2015; 33: 1411–17 25. Ware MJ, Tinger S, Colbert KL, et al. Radiofrequency treatment alters cancer cell phenotype Sci Rep 2015; 5: 12083 26. van Valenberg FJP, van der Heijden AG, Lammers RJM, et al. Intravesical radiofrequency induced hy‑ perthermia enhances mitomycin C accumulation in tumour tissue Int J Hyperthermia 2018; 34(7): 988–993 27. Curley SA, Palalon F, Sanders KE, Koshkina NV. The effects of non‑invasive radiofrequency treatment and hyperthermia on malignant and nonmalignant cells Int J Environ Res Public Health 2014; 3: 11(9): 9142–53 28. Lammers RJ, Witjes JA, Inman BA, et al. The role of a combined regimen with intravesical chemothe‑ rapy and hyperthermia in the management of non muscle invasive bladder cancer: A systematic review Eur Urol 2011; 60: 81–93 29. Brummelhuis ISG, Wimper Y, Witjes‑van Os HGJM, et al. Long‑Term Experience with Radiofrequency ‑Induced Hyperthermia Combined with Intravesical Chemotherapy for Non‑Muscle Invasive Bladder Cancer Cancers 2021; 13: 377 30. Colombo R, Da Pozzo LF, Lev A, et al. Local microwave hyperthermia and intravesical chemotherapy as bladder sparing treatment for selected multifocal and unresectable superficial bladder tumors J Urol 1998; 159: 783–7 31. Brisuda A, Babjuk M, Stolz J. Intravezikální chemoterapie s využitím tepelné energie u pacientů s uro‑ teliálním karcinomem močového měchýře bez invaze svaloviny Ces Urol 2017; 21(2): 122–128
RkJQdWJsaXNoZXIy NDA4Mjc=